← Case Library

Clause 12.1

⚖ 40 PMCPA cases 🔒 Members see all 40 cases

What this clause covers

Governs relationships and financial interactions between pharmaceutical companies and healthcare professionals. Payments for consultancy, speaking, or advisory work must be documented, at fair market value, and for genuine services. Excessive or undocumented payments are a recurring breach area.

PMCPA Cases — Clause 12.1

40 cases
📅 8 Mar 2026 · Boehringer Ingelheim

Lilly and Boehringer Ingelheim: journal insert presented as sponsored supplement found to be disguised promotion (AUTH/2213/3/09, AUTH/2214/3/09)

Clause 12.1 Clause 2
📅 8 Mar 2026 · Boehringer Ingelheim

Anonymous doctor v Lilly and Boehringer Ingelheim: sponsored journal supplement found to be disguised promotion

Clause 12.1 Clause 2
📅 8 Mar 2026 · Stiefel Laboratories

Stiefel: Duac promotion—misleading indication via acne grading chart, unsubstantiated “within a week” claim, and disguised journal insert (AUTH/2244/6/09)

Clause 12.1 Clause 3.2 Clause 7.10 Clause 7.2 +3 more
🔒

See all 40 cases for Clause 12.1

Case Library members get full access to every PMCPA ruling, searchable by clause, company, outcome, and sanction.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

Already a member? Sign in

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free